✦ LIBER ✦

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

✍ Scribed by Paul Gaglio, Kwaku Marfo, Joseph Chiodo III

Book ID: 118298860
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 449 KB
Volume: 57
Category: Article
ISSN: 0163-2116
DOI: 10.1007/s10620-012-2276-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vasopressin V2 Receptor Blockade With To

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

✍ Mihai Gheorghiade; Stephen S. Gottlieb; James E. Udelson; Marvin A. Konstam; Fra 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

Conivaptan, a Vasopressin-Receptor Antag

Conivaptan, a Vasopressin-Receptor Antagonist, for the Treatment of Hyponatremia in Patients with and without Underlying Heart Failure

✍ Jalal K. Ghali; Bo Yan; Bruce McNutt 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Limitation of the model for end-stage li

Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications

✍ Teh-Ia Huo; Han-Chieh Lin; Jaw-Ching Wu; Ming-Chih Hou; Fa-Yauh Lee; Pui-Ching L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

New insights into the pathophysiology an

New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma

✍ Hui Wang; Gil Yosipovitch 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

The 1-year and 3-month prognostic utilit

The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis

✍ Edoardo Giannini; Federica Botta; Emanuela Testa; Paola Romagnoli; Simone Polega 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 82 KB